We found that MEK inhibitors reversed the increased DUSP4 protein levels (Fig. 2E and Additional file 1: Fig. S9C) as well as DUSP4 induced proliferation (Fig. 2F) suggesting MEK inhibitors as a therapeutic strategy in BC with downregulated DUSP4 expression. This evidence concerns the gene DUSP4 and breast cancer.